Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
drugs
3
×
life sciences
national blog main
alnylam pharmaceuticals
aminolevulinic acid
boston
fda
givosiran
rna interference
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
blueprint medicines
boulder/denver blog main
boulder/denver top stories
cancer
companion diagnostic
detroit blog main
detroit top stories
dna sequencing
entrectinib
express scripts
foundation medicine
indiana blog main
indiana top stories
josh bilenker
keytruda
larotrectinib
loxo oncology
melanie nallicheri
merck
national
national top stories
new england journal of medicine
new york blog main
new york top stories
What
drug
medicine
second
3
×
alnylam
fda
interference
new
pharmaceuticals
rna
rnai
seek
speedy
ago
approval
approved
cancer
cleared
data
deeper
dna
far
fingerprint
genetic
going
indicated
market
matter
nasdaq
nd
nod
ok
oks
quick
targets
time
tissues
tumor's
weeks
won’t
world
Language
Current search:
second
×
drugs
×
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
